Equities

Henan Lingrui Pharmaceutical Co Ltd

600285:SHH

Henan Lingrui Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.81
  • Today's Change-0.75 / -3.48%
  • Shares traded7.11m
  • 1 Year change+22.85%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

  • Revenue in CNY (TTM)3.56bn
  • Net income in CNY675.80m
  • Incorporated1999
  • Employees2.53k
  • Location
    Henan Lingrui Pharmaceutical Co LtdNo.666, Jiangjun Road, Xinxian CountyXINYANG 465550ChinaCHN
  • Phone+86 3 762973569
  • Fax+86 3 762987888
  • Websitehttp://www.lingrui.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.58bn421.47m12.04bn1.55k29.074.60--7.641.881.887.1411.910.42861.193.671,020,281.0011.585.8616.997.5967.1255.4127.0117.200.91224.020.347727.5958.6932.2426.2029.9927.32--
Guobang Pharma Ltd5.71bn702.28m12.13bn4.23k17.221.55--2.121.261.2610.2614.030.55993.297.841,350,536.006.8710.368.8814.2423.8727.4912.2715.011.70--0.199218.24-6.4910.28-33.4923.7735.60--
Henan Lingrui Pharmaceutical Co., Ltd.3.56bn675.80m12.23bn2.53k17.964.23--3.431.201.206.345.100.74892.2410.181,408,620.0014.2010.6823.5216.5672.3574.4218.9614.920.9579--0.007372.8010.3110.0322.0918.49-16.4739.77
Tibet Rhodiola Pharmaceutical Holding Co2.94bn737.44m12.25bn601.0014.743.38--4.172.582.589.6911.260.62641.546.794,894,779.0015.8012.4420.8315.7193.3690.5125.2220.433.447.740.126450.4122.6924.98116.5630.01-1.4848.97
Zhejiang CONBA Pharmaceutical Co., Ltd.6.46bn486.79m12.26bn8.41k24.951.84--1.900.19120.19122.542.590.6182.394.56768,224.604.986.776.9310.5051.4763.248.0611.101.24--0.078142.3212.20-0.826765.20-6.21-11.645.92
Data as of Nov 22 2024. Currency figures normalised to Henan Lingrui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

20.96%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 202432.81m5.59%
First Seafront Fund Management Co., Ltd.as of 30 Jun 202432.21m5.49%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202417.45m2.98%
Harvest Fund Management Co., Ltd.as of 30 Jun 20248.82m1.50%
China Southern Asset Management Co., Ltd.as of 30 Jun 20248.35m1.42%
China Universal Asset Management Co., Ltd.as of 30 Jun 20248.10m1.38%
Yinhua Fund Management Co., Ltd.as of 30 Jun 20245.09m0.87%
Oriental Alpha Fund Management Co. Ltd.as of 30 Jun 20244.35m0.74%
China Asset Management Co., Ltd.as of 30 Jun 20243.06m0.52%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20242.69m0.46%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.